| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
1,5-Dihexadecyl N-(3-carboxy-1-oxopropyl)-L-glutamate does not have a specific biological receptor target. It functions as a structural lipid that facilitates the formation of phospholipid vesicles and enhances protein encapsulation efficiency.
|
|---|---|
| ln Vitro |
In vitro, this lipid is used in the synthesis and preparation of phospholipid vesicles to improve protein encapsulation efficiency. The compound assists in achieving uniform vesicle sizes through freeze-thaw and extrusion methods.
|
| ln Vivo |
In vivo, this lipid is primarily used as an excipient in drug delivery formulations. The enhanced protein encapsulation efficiency provided by this lipid can improve the pharmacokinetic and therapeutic profiles of protein-based therapeutics in animal models.
|
| Enzyme Assay |
In vitro vesicle formation involves dissolving the lipid with other phospholipids in organic solvent, drying to form a lipid film, and hydrating with aqueous buffer containing the protein cargo. The vesicles are subjected to freeze-thaw cycles and extrusion through polycarbonate membranes to achieve uniform size. Encapsulation efficiency is determined by measuring the amount of protein associated with the vesicles after separation from unencapsulated protein.
|
| Cell Assay |
Cellular assays for this lipid are typically performed as part of protein delivery studies. Cells are treated with protein-loaded vesicles, and protein uptake, intracellular distribution, and biological activity are assessed. Encapsulation efficiency and vesicle stability are key parameters evaluated.
|
| Animal Protocol |
In vivo animal studies involve administration of protein-loaded vesicles containing this lipid in rodent models. Tissue distribution, pharmacokinetics, and therapeutic efficacy of the encapsulated protein are evaluated. The improved encapsulation efficiency provided by this lipid can enhance protein delivery and therapeutic outcomes.
|
| ADME/Pharmacokinetics |
As a lipid excipient, pharmacokinetic properties depend on the formulation and the encapsulated protein. The lipid component contributes to vesicle stability and circulation time. The compound is metabolized through normal lipid metabolism pathways.
|
| Toxicity/Toxicokinetics |
1,5-Dihexadecyl N-(3-carboxy-1-oxopropyl)-L-glutamate is generally considered biocompatible as a lipid excipient. Standard safety precautions for handling lipids should be followed. No significant toxicity has been reported for the compound itself.
|
| References | |
| Additional Infomation |
1,5-Dihexadecyl N-(3-carboxy-1-oxopropyl)-L-glutamate is a lipid that plays a crucial role in the synthesis of phospholipid vesicles and enhances the encapsulation efficiency of proteins. The compound assists in achieving uniform vesicle sizes through freeze-thaw and extrusion methods. It is a valuable tool for protein delivery research.
|
| Molecular Formula |
C41H77NO7
|
|---|---|
| Molecular Weight |
696.053
|
| Exact Mass |
695.57
|
| CAS # |
125401-63-0
|
| PubChem CID |
10327351
|
| Appearance |
White to off-white solid powder
|
| LogP |
14.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
40
|
| Heavy Atom Count |
49
|
| Complexity |
788
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(CCC(N[C@H](C(OCCCCCCCCCCCCCCCC)=O)CCC(OCCCCCCCCCCCCCCCC)=O)=O)(O)=O
|
| InChi Key |
WTBOZUQAGVMYTM-QNGWXLTQSA-N
|
| InChi Code |
InChI=1S/C41H77NO7/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-35-48-40(46)34-31-37(42-38(43)32-33-39(44)45)41(47)49-36-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h37H,3-36H2,1-2H3,(H,42,43)(H,44,45)/t37-/m0/s1
|
| Chemical Name |
4-[[(2S)-1,5-dihexadecoxy-1,5-dioxopentan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol: 25 mg/mL (35.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4367 mL | 7.1834 mL | 14.3668 mL | |
| 5 mM | 0.2873 mL | 1.4367 mL | 2.8734 mL | |
| 10 mM | 0.1437 mL | 0.7183 mL | 1.4367 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
